Join Conscio Group and leading industry experts on June 5, 2025, at 2:00 PM CET (expected duration up to 2 hours) for an exclusive webinar exploring the shifting balance between analytical similarity and clinical data in biosimilar development.
With regulatory expectations evolving, the importance of high-quality CMC and PK data has never been greater. Robust analytical evidence may reduce or even eliminate the need for large Phase 3 efficacy studies – but how do you convincingly demonstrate biosimilarity?
Program highlights:
- The Future of Biosimilars: Leveraging Extensive Analytical Similarity for Regulatory Success
- Regulatory Strategies for Biosimilars: Past and Future.
- Patient Safety: Building Trustworthy Clinical Data for Biologics Approval
Speakers:
- Dr. Thakara Rama Velisetty – CMC Sr Manager, IQVIA
- Dr. Parvinder Punia – Co-Founder, Pharmexon
- Jiří Juchelka, MD, MBA – Principal investigator, Conscio Group
Moderator:
Stephan Holl, CEO, Conscio Group
Take this opportunity to gain expert insights, ask questions live, and get ahead of the curve in your biosimilar development strategy.
[Register here] to secure your spot. Participation is free!
Want to explore what we covered last time? Watch the recording of our previous session:
[Expediting Biosimilar Development – Webinar Recording]
